Key points
- "Weight loss injection" searches more than tripled between April 2025 and early 2026.
- January is the peak month: more than double the searches of November.
- Semaglutide searches nearly tripled in March 2026, when generics launched.
- The four main GLP-1 medicine names draw more than twice the searches of "weight loss".
Key findings
- Searches for "weight loss injection" more than tripled in a year, from about 6,600 a month in April and May 2025 to 22,200 in January and March 2026.
- New Year is the peak: January 2026 searches were more than double November 2025's (22,200 vs 9,900).
- The semaglutide patent expiry set off a spike: searches for "semaglutide" jumped from 49,500 in February 2026 to 1,35,000 in March 2026, the month generics launched, and stayed above pre-expiry levels afterwards.
- Ozempic is the name Indians search most, at about 1,65,000 searches a month, even though in India it's approved for type 2 diabetes, not weight management.
- The four main GLP-1 medicine names together draw about 3.2 lakh searches a month, more than twice the searches for "weight loss" itself (about 1.35 lakh).
- Safety is a big worry: "Ozempic side effects" and "Mounjaro side effects" draw about 24,700 searches a month together, three times the searches for "Mounjaro price in India".
Weight loss injection searches more than tripled
See the numbers
| Month | Searches |
|---|---|
| Apr 2025 | 6,600 |
| May 2025 | 6,600 |
| Jun 2025 | 8,100 |
| Jul 2025 | 9,900 |
| Aug 2025 | 8,100 |
| Sep 2025 | 9,900 |
| Oct 2025 | 9,900 |
| Nov 2025 | 9,900 |
| Dec 2025 | 12,100 |
| Jan 2026 | 22,200 |
| Feb 2026 | 18,100 |
| Mar 2026 | 22,200 |
| Apr 2026 | 12,100 |
Interest climbed steadily through 2025 and almost doubled from December to January, when New Year goals and new medicine launches came together.
The patent expiry spike
See the numbers
| Month | Searches |
|---|---|
| Aug 2025 | 40,500 |
| Sep 2025 | 40,500 |
| Oct 2025 | 33,100 |
| Nov 2025 | 40,500 |
| Dec 2025 | 49,500 |
| Jan 2026 | 49,500 |
| Feb 2026 | 49,500 |
| Mar 2026 | 1,35,000 |
| Apr 2026 | 90,500 |
| May 2026 | 74,000 |
| Jun 2026 | 74,000 |
| Jul 2026 | 74,000 |
| Aug 2026 | 60,500 |
Novo Nordisk's main semaglutide patent in India expired on 20 March 2026, and generic versions from Indian companies launched within days, from about ₹1,300 a month. Searches nearly tripled that month. Read about generic semaglutide.
What India searches for
See the numbers
| Search term | Searches a month |
|---|---|
| Ozempic | 1,65,000 |
| weight loss (for reference) | 1,35,000 |
| Mounjaro | 74,000 |
| semaglutide | 60,500 |
| Wegovy | 18,100 |
| Ozempic side effects | 14,800 |
| weight loss injection | 12,100 |
| Mounjaro side effects | 9,900 |
| Mounjaro price in India | 8,100 |
Brand names dominate. Many people search for Ozempic when they mean any weight-loss injection, which is one reason clear, accurate information matters.
What this means for patients
- Interest is high, and so is the risk of fake or unsupervised treatment. These are prescription medicines that need a doctor's assessment.
- Prices vary widely by medicine and dose. Our monthly price tracker lists every one.
- Side effects are common but usually manageable with slow dose increases. See Mounjaro and Ozempic side effects.
Using this report
You're welcome to quote these findings and charts. Please credit Lean Life, "Weight loss searches in India 2026" and link to this page. For interviews with our doctors, see our press page.
Questions
Where does this data come from?
Estimated monthly Google searches in India, in English, from Ubersuggest's keyword data, collected on 16 November 2026.
Can I use these charts?
Yes, with credit to Lean Life and a link to this page.
Will this report be updated?
Yes. We plan to refresh it as new data becomes available.


